Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

The new PanOptix™ trifocal IOL: clinical results of the first 100 eyes implanted

Poster Details

First Author: K. Gundersen NORWAY

Co Author(s):                        

Abstract Details

Purpose:

The purpose of this study was to study postoperative data on subjective refraction, near, intermediate and distance visual acuity and defocus curves for patients with bilateral implantation of the Acrysof® PanOptix™ IOL.

Setting:

Private Eye Clinic in Haugesund, Norway

Methods:

Single-center non-comparative open-labelled prospective study. It is planned to obtain 40 evaluable subject data sets. A total number of 50 patients will be recruited to account for a 20% dropout rate. Follow up visits at Day 1, Week 1, Month 1 and Month 3 after surgery. Defocus curve data will be collected 3-6 months after surgery. A validated subjective questionnaire assessed the overall patient's satisfaction and the amount of photic phenomena after surgery. At present, we can report postoperative data from 44 subjects, (88 eyes). 30 subjects, (60 eyes) have passed the 3 months visit after surgery.

Results:

Mean age was 61.3 ± 9.2, (47-85). Mean preoperative MSE was 0.37 ± 2.07 (-8.63-+4.38). Mean preoperative cylinder was -0.62 ± 0.49. At 3 months: MSE = -0.03 D ± 0.35 (-0.75 – 0.63). Mean cylinder = -0.4 D ± 0.38. Mean UCDVA = 1.04 ± 0.22 (0.65-1.50), BSCVA = 1.16 ± 0.12 (0.9-1.50). Mean preferred reading distance = 38.6cm ± 3.8. In a scale from 1 to 10, the mean overall satisfaction rate was 9.12 ± 0.2. 22.4 % reported subjective photic phenomena, but none had significant negative impact on daily activities. Results from defocus curve data will be presented. No serious per and postoperative complication occurred in this series of study subjects.

Conclusions:

Based on data 3 months after implantation, Acrysof® PanOptix™ IOL were very well accepted with high rate of patient satisfaction and low rate of visual side effects. Acrysof ®PanOptix™ IOL showed a very narrow range of refractive variation and a wide range of satisfactory visual acuity at near, intermediate and at distance.

Financial Disclosure:

NONE

Back to Poster listing